Abstract
We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone. The remarkable clinical improvement in joint symptoms within 24 h and in glycemic control during a 6-month period gives anakinra a potential therapeutic role in the management of gout and type 2 diabetes. When anakinra was discontinued, a gout attack occurred within 3–25 days in all three patients. The contribution of anakinra in the treatment of such syndromes is encouraging, but requires further studies to establish its long-term efficacy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Joost PH, van Der Meer JW (2006) The inflammasome: a linebacker of innate defense. N Engl J Med 355:730–732
Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241
Cronstein BN, Sunkureddi P (2013) Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol 19:19–29
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110
Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801
Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T et al (2004) Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 101:8138–8143
Ardestani A, Sauter NS, Paroni F, Dharmadhikari G, Cho JH, Lupi R et al (2011) Neutralizing interleukin-1beta (IL-1beta) induces beta-cell survival by maintaining PDX1 protein nuclear localization. J Biol Chem 286:17144–17155
Carstensen M, Herder C, Kivimäki M, Jokela M, Roden M, Shipley MJ et al (2010) Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 59:1222–1227
Dinarello CA (2011) Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med 269:16–28
Dinarello CA, van der Meer JW (2013) Treating inflammation by blocking interleukin-1 in humans. Semin Immunol [Epub ahead of print]
So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9:R28
Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L et al (2013) Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 15:R123
Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839–1848
Schumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP et al (2012) Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 64:1462–1470
Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M (1986) Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232:1545–1547
van Asseldonk EJ, Stienstra R, Koenen TB, van Tits LJ, Joosten LA, Tack CJ et al (2010) The effect of the interleukin-1 cytokine family members IL-1 F6 and IL-1 F8 on adipocyte differentiation. Obesity (Silver Spring) 18:2234–2236
Savic S, Dickie LJ, Wittmann M, McDermott MF (2012) Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol 26:505–533
Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526
Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663–1668
Mandrup-Poulsen T, AIDA study group (2013) Interleukin-1 antagonists for diabetes. Expert Opin Investig Drugs 22:965–979
Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668
Richette P, Clerson P, Périssin L, Flipo RM, Bardin T (2013) Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis [Epub ahead of print]
Tran AP, Edelman J (2011) Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 14:e33–e37
Disclosures
Conflict of interest
Luca Cantarini receives Grant/Research support from Novartis, SOBI, and is a consultant for Novartis, SOBI. The others authors have disclosed no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vitale, A., Cantarini, L., Rigante, D. et al. Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol 34, 981–984 (2015). https://doi.org/10.1007/s10067-014-2601-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-014-2601-7